Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J, Elemary M, Linn SM, Novitzky-Basso I, Culos S, Tan SK, Kelly K, Deotare U, Xenocostas A, Hamad N, Law A, Kumar R, Kim DDH. White J, et al. Among authors: kim ddh. Transplant Cell Ther. 2023 Feb;29(2):120.e1-120.e9. doi: 10.1016/j.jtct.2022.11.025. Epub 2022 Nov 30. Transplant Cell Ther. 2023. PMID: 36460202 Free article. Clinical Trial.
Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD.
Novitzky-Basso I, Patriquin C, Linn SM, Chiarello C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Novitzky-Basso I, et al. Among authors: kim ddh. Transplant Cell Ther. 2023 Dec;29(12):773.e1-773.e10. doi: 10.1016/j.jtct.2023.09.021. Epub 2023 Oct 4. Transplant Cell Ther. 2023. PMID: 37797719 Free article.
Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
Salas MQ, Alfaro-Moya T, Atenafu EG, Datt Law A, Lam W, Pasic I, Novitzky-Basso I, Santos Carreira A, Chen C, Michelis FV, Gerbitz A, Howard Lipton J, Kim DDH, Kumar R, Mattsson J, Viswabandya A. Salas MQ, et al. Among authors: kim ddh. Transplant Cell Ther. 2024 May;30(5):536.e1-536.e13. doi: 10.1016/j.jtct.2024.01.075. Epub 2024 Jan 27. Transplant Cell Ther. 2024. PMID: 38281592
Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study.
Pasic I, Moya TA, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J. Pasic I, et al. Among authors: kim ddh. Transplant Cell Ther. 2024 Jul;30(7):681.e1-681.e11. doi: 10.1016/j.jtct.2024.04.014. Epub 2024 Apr 20. Transplant Cell Ther. 2024. PMID: 38648898
Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease.
Shapiro RM, Shin E, Law AD, Lam W, Michelis FV, Viswabandya A, Kumar R, Lipton JH, Messner H, Mattsson J, Kim DDH. Shapiro RM, et al. Among authors: kim ddh. Biol Blood Marrow Transplant. 2019 Sep;25(9):1761-1769. doi: 10.1016/j.bbmt.2019.05.029. Epub 2019 Jun 4. Biol Blood Marrow Transplant. 2019. PMID: 31170520 Free article. Clinical Trial.
138 results